These results defined the EPO-JAK2-STAT3-VEGF pathway as an underlying mechanism of the rhEPO proangiogenic property, which in turn promotes tumor growth in pituitary adenomas. This evidence concerns the gene JAK2 and pituitary gland adenoma.